TBG Diagnostics Ltd fka TDLAF

[busker]

Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases

Brisbane, Australia. 2 November 2007: Progen Pharmaceuticals Limited (ASX:PGL; NASDAQ:PGLA) today announced that Dr James Garner, Progen’s Vice President of Clinical and Medical Affairs will present a poster entitled “The Interactive Effect of Prognostic Factors and PI-88 Use on the Delay of HCC Recurrence Following Curative Partial Hepatic Resection” at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA1 on Saturday, 3 November 2007.

The poster presentation will be made available on Progen’s website www.progen-pharma.com from approximately 9am (Brisbane time) Saturday 3 November 2007.

1Each year, the American Association for the Study of Liver Diseases brings together over 6,000 hepatologists and hepatology health professionals from around the world for its annual meeting to meet and exchange the latest liver disease research, and discuss treatment outcomes.

Link to poster preso. (for the science minded) <:))

http://www.progen-pharma.com/prs/AASLD%20HCC%20Company%20Poster_Final%20sec.pdf